deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00703326

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer

Sponsor: Eli Lilly and Company

Conditions Breast Cancer
Interventions Placebo docetaxel ramucirumab (IMC-1121B)
Updated 15 times since 2017 Last updated: Nov 3, 2021 Started: Aug 6, 2008 Primary completion: Mar 31, 2013 Completion: Nov 19, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Cancer and is currently completed. Eli Lilly and Company leads this study, which shows 15 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Dec 2021 · 8 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2021 — Jan 2022 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Apr 2021 — Dec 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alexandria, Egypt , Alhambra, United States , Alicante, Spain , Alton, United States , Arequipa, Peru , Atlanta, United States , Auckland, New Zealand , Aurora, United States , Badalona, Spain and 182 more locations